Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 19.73 USD -0.15% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Schrodinger Inc?
Write Note

Schrodinger Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Schrodinger Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Schrodinger Inc
NASDAQ:SDGR
Other Non-Cash Items
$21.7m
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Other Non-Cash Items
$419.9m
CAGR 3-Years
17%
CAGR 5-Years
30%
CAGR 10-Years
40%
Inspire Medical Systems Inc
NYSE:INSP
Other Non-Cash Items
$101.1m
CAGR 3-Years
61%
CAGR 5-Years
93%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Other Non-Cash Items
$59m
CAGR 3-Years
61%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Other Non-Cash Items
$63.4m
CAGR 3-Years
-9%
CAGR 5-Years
8%
CAGR 10-Years
18%
W
Waystar Holding Corp
NASDAQ:WAY
Other Non-Cash Items
$22.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Schrodinger Inc
Glance View

Market Cap
1.4B USD
Industry
Health Care

In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry. Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.

SDGR Intrinsic Value
15 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Schrodinger Inc's Other Non-Cash Items?
Other Non-Cash Items
21.7m USD

Based on the financial report for Sep 30, 2024, Schrodinger Inc's Other Non-Cash Items amounts to 21.7m USD.

What is Schrodinger Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 3Y
52%

The average annual Other Non-Cash Items growth rates for Schrodinger Inc have been 52% over the past three years .

Back to Top